Brigatinib is an oral tyrosine kinase inhibitor (TKI) with potent activity against a broad range of anaplastic lymphoma kinase (ALK) gene resistance mutations, including the fusion protein EML4‐ALK found in ~ 5% of patients with non‐small cell lung cancer (NSCLC).1, 2, 3. Here, ALK is linked to lung cancer.